

### heartbeam.com


#### Investor Relations

Chris Tyson  
Executive Vice President  
MZ North America  
+1-949-491-8235  
BEAT@mzgroup.us


### NASDAQ: BEAT

Share Price <sup>1</sup>	\$0.96
Proforma Market Cap <sup>2</sup>	\$53.3M
Proforma Cash & Cash Equivalents <sup>2</sup>	\$12.4M
Proforma Shares Out <sup>2</sup>	55.5M
Float <sup>3</sup>	33.9M

1) As of May 15, 2026  
2) Proforma – Q1 2026 10-Q + April/May 2026 Offering & Overallotment  
3) Source: Yahoo Finance

[How to Use the HeartBeam System](#) 

HeartBeam is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.



## Executing on a \$40B Cardiac Monitoring Platform Opportunity

- **Ability to serve 50M+ patients** across multiple applications and form factors
- **Commercial Launch Underway** for arrhythmia assessment
- **On-Demand 12-Lead Patch poised to disrupt \$2B patch market**
- Rapidly advancing clinical validation to support **indication expansion into Heart Attack Detection**
- **Partnering with Mt Sinai** to bring AI screening and predictive algorithms to the HeartBeam System

#### Strong IP and Robust Clinical Evidence

- ✔ 25 Issued Patents Worldwide
- ✔ 14 Clinical Papers & Presentations

#### FDA 510(k) Clearances for Arrhythmia Detection

- ✔ 12/2024: The HeartBeam System
- ✔ 12/2025: 12-Lead Synthesis Algorithm

#### Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Heart Attack Detection, AI algorithm and 12-lead patch products are not cleared by FDA and not available for sale in the United States or other geographies. Refer to the Company's Cleared Indications for Use at [HeartBeam Indications](#) for details on the intended use of its technology.



# Focused Commercial Launch Underway

- Flagship commercial sites across four target markets: New York, Dallas, South Florida, and Southern California.
- Initial foothold in structured direct-pay healthcare segment, representing ~5 million U.S. patients.
- Cash flow break-even at ~30,000 patients
- Scaling efficiently without the need for a large field force



## On-Demand 12-Lead Patch<sup>1</sup>: Disrupting the Patch Market

### TODAY'S PATCH MARKET

\$2B revenue market with existing reimbursement

Devices are 1-3 leads, which limit applications to arrhythmia detection and monitoring

Mobile Cardiac Telemetry (MCT) segment has highest reimbursement and fastest growth

Sources: [ReAnIn Reports](#), [GM Insights](#)



[Watch the video](#)



Clinical grade 12-Lead ECG in a patch form factor

Continuous 1-Lead mode matches performance of existing systems

On-demand 12-Lead ECG mode **expands segment into ischemia detection**

Pilot study to detect ischemia initiated

Positioned to take share and expand patch market



## Heart Attack Detection<sup>1</sup>

Clinical validation to support indication expansion into heart attack detection is rapidly advancing. ALIGN-ACS pilot study underway in Europe and enrolling ahead of schedule.

**20M+** high-risk patients in the U.S.

Patients can't recognize a heart attack at home

12-Lead ECG is only in hospitals

3-4 hour delays = death or heart failure

### Why We Win

Two proof of concept studies show HeartBeam is similar to standard 12-Lead ECG

Baseline ECG improves accuracy over single ECG

Same device → expanded indication (no new hardware)

De Luca G. Circulation. 2004 Mar 16;109(10):1223-5 Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466.

## Accelerating AI-ECG Algorithms<sup>1</sup>



Mount Sinai Hospital

• Accelerates development of **personalized cardiac AI algorithms** on the **HeartBeam platform** across **wellness and clinical use cases** including **assessing heart attack risk**.

• Expands HeartBeam beyond rhythm monitoring **into longitudinal 12-lead ECG monitoring** anytime, anywhere outside traditional care settings.



**DISCLAIMER:** This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument or to participate in any trading strategy. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. This document has been furnished to you solely for your information.